---
title: "Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300122.SZ.md"
symbol: "300122.SZ"
name: "Chongqing Zhifei Biological Products Co.,Ltd."
industry: "Biotechnology"
datetime: "2026-05-21T07:06:08.167Z"
locales:
  - [en](https://longbridge.com/en/quote/300122.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300122.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300122.SZ.md)
---

# Chongqing Zhifei Biological Products Co.,Ltd. (300122.SZ)

## Company Overview

Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide vaccine; Haemophilus Influenza type B conjugate vaccine; mycobacterium injection under the Vaccae brand; and meningococcal group A and C conjugate vaccine. It also provides cold storage, refrigerated vehicles, and cold roll boxes; and customs clearance and registration of imported vaccines. The company was founded in 2002 and is based in Chongqing, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.zhifeishengwu.com](https://www.zhifeishengwu.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: D (0.78)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 66 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -48.52% |  |
| Net Profit YoY | -7970.64% |  |
| P/B Ratio | 2.28 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 35216630036.46 |  |
| Revenue | 8738163127.35 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -64.31% | E |
| Profit Margin | -168.87% | E |
| Gross Margin | 29.16% | C |
| Revenue YoY | -48.52% | E |
| Net Profit YoY | -7970.64% | E |
| Total Assets YoY | -39.82% | E |
| Net Assets YoY | -48.53% | E |
| Cash Flow Margin | -34.59% | E |
| OCF YoY | -48.52% | E |
| Turnover | 0.23 | D |
| Gearing Ratio | 45.99% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Chongqing Zhifei Biological Products Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-48.52%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-7970.64%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.28",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "35216630036.46",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8738163127.35",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-64.31%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-168.87%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "29.16%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-48.52%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-7970.64%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-39.82%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-48.53%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-34.59%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-48.52%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.23",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "45.99%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.39 | 46/81 | 218.22 | 186.19 | 181.22 |
| PB | 2.28 | 33/81 | 1.76 | 1.59 | 1.41 |
| PS (TTM) | 4.03 | 10/81 | 4.26 | 3.83 | 3.27 |
| Dividend Yield | 0.00% | - | 5.03% | 1.00% | 0.92% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T16:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 33% |
| Overweight | 1 | 17% |
| Underweight | 1 | 17% |
| Sell | 1 | 17% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 14.49 |
| Highest Target | 32.00 |
| Lowest Target | 14.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300122.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300122.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300122.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300122.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**